- Products
- Flow Cytometry
- Biotheraputics Discovery
- Custom Services
- Bioanalytical Antibodies
- Tools and Resources
- Antibody Support
- Order Status
- Quick Order
- Support
Browsing Modes for Business Users
-
Create mode – the default mode when you create a requisition and PunchOut to Bio-Rad. You can create and edit multiple shopping carts
-
Edit mode – allows you to edit or modify an existing requisition (prior to submitting). You will be able to modify only the cart that you have PunchedOut to, and will not have access to any other carts
-
Inspect mode – when you PunchOut to Bio-Rad from a previously created requisition but without initiating an Edit session, you will be in this mode. You cannot modify any Cart contents
Anti-Tocilizumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Risankizumab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of tocilizumab and biosimilars
Develop highly selective and sensitive PK and ADA assays for tocilizumab (Actemra, RoActemra) using our range of ready-made anti-idiotypic antibodies.
- Inhibitory and non-inhibitory antibodies specific to tocilizumab
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch to batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Tocilizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Tocilizumab Inhibitory Type 1 |
HCA252 |
AbD21362 |
Fab-FH1 |
0.9 |
PK bridging ELISA |
|
|
HCA253 |
AbD21338_hIgG1 |
hIgG1 HRP |
0.1 |
PK bridging ELISA ADA control |
||
|
HCA254 |
AbD21364_hIgG1 |
hIgG1 |
0.3 |
ADA control |
||
|
HCA255 |
AbD21346_hIgG |
hIgG1 |
6.2 |
ADA control |
||
|
HCA256 |
AbD21345_hIgG1 |
hIgG1 |
15 |
ADA control |
||
|
Tocilizumab & Tocilizumab-IL6R Non-inhibitory Type 2 |
HCA257 |
AbD22155_hIgG1 |
hIgG1 HRP |
31 |
PK bridging ELISA
|
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Anti-Tocilizumab Inhibitory Antibodies (Type 1)
Type 1 anti-tocilizumab antibodies inhibit the binding of the drug tocilizumab to its target, human interleukin-6 receptor (IL-6R). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in high, medium and lower affinity, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Anti-Tocilizumab Non-Inhibitory Antibody (Type 2)
The type 2 anti-tocilizumab antibody binds to the tocilizumab idiotope, but does not inhibit the binding of tocilizumab to IL-6R. It can therefore be used in combination with a type 1 antibody in a PK bridging ELISA to measure free and partially bound drug, which is equivalent to total drug when trough serum levels are above 10 µg/ml.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Tocilizumab PK bridging ELISA using antibodies HCA252 and HCA253P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Tocilizumab PK bridging ELISA using antibodies HCA252 and HCA257P.
Schematic image of PK bridging ELISA measuring free and partially bound drug. Type 1 anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), drug target (red), type 2 anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
ADA Bridging ELISA
Fig. 3. Tocilizumab ADA bridging ELISA using antibody HCA253, HCA254, HCA255 or HCA256.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.